

1 **Title:** Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in
2 convalescent individuals

3

4 **Authors:** Alena J. Markmann^{1*}, Natasa Giallourou², D. Ryan Bhowmik³, Yixuan J. Hou⁴, Aaron
5 Lerner⁵, David R. Martinez⁴, Lakshmanane Premkumar³, Heather Root¹, David van Duin¹, Sonia
6 Napravnik^{1,4}, Stephen D. Graham³, Quique Guerra³, Rajendra Raut³, Christos J. Petropoulos⁶,
7 Terri Wrin⁶, Caleb Cornaby⁷, John Schmitz^{3,7}, JoAnn Kuruc^{1,8}, Susan Weiss⁷, Yara Park⁷, Ralph
8 Baric^{3,4}, Aravinda M. de Silva³, David M. Margolis^{1,3,4,8}, Luther A. Bartelt¹

9

10 ¹Department of Medicine, Division of Infectious Diseases, University of North Carolina School of
11 Medicine, Chapel Hill NC 27599, USA

12 ²Centre of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research
13 Center, University of Cyprus, Nicosia, Cyprus.

14 ³Department of Microbiology and Immunology, University of North Carolina School of Medicine,
15 Chapel Hill NC 27599, USA

16 ⁴Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

17 ⁵Department of Medicine, University of North Carolina School of Medicine, Chapel Hill NC
18 27599, USA

19 ⁶LabCorp-Monogram Biosciences, South San Francisco, CA 94080

20 ⁷Department of Pathology & Laboratory Medicine, University of North Carolina School of
21 Medicine, Chapel Hill NC 27599, USA

22 ⁸UNC HIV Cure Center, University of North Carolina School of Medicine, Chapel Hill NC 27599,
23 USA

24

25 *Address correspondence to Alena J. Markmann: email alena.markmann@unchealth.unc.edu,
26 phone 585-880-5812.

27 Alternate correspondence to Luther A. Bartelt: luther_bartelt@med.unc.edu

28

29 Running Title: Sex gap in antibody response to COVID-19

30

31 Keywords: Antibodies, SARS-CoV-2, Immunology, neutralizing antibodies

32

33

34

35

36

37

38 **Abstract**

39 The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
40 syndrome-related coronavirus-2 (SARS-CoV-2) has now caused over 2 million deaths
41 worldwide and continues to expand. Currently, much is unknown about functionally neutralizing
42 human antibody responses and durability to SARS-CoV-2. Using convalescent sera collected
43 from 101 COVID-19 recovered individuals 21-212 days after symptom onset with forty-eight
44 additional longitudinal samples, we measured functionality and durability of serum antibodies.
45 We also evaluated associations between individual demographic and clinical parameters with
46 functional neutralizing antibody responses to COVID-19. We found robust antibody durability out
47 to six months, as well as significant positive associations with the magnitude of the neutralizing
48 antibody response and male sex. We also show that SARS-CoV-2 convalescent neutralizing
49 antibodies are higher in individuals with cardio-metabolic comorbidities.

50
51
52
53
54
55
56

57 **Significance:** In this study we found that neutralizing antibody responses in COVID-19
58 convalescent individuals vary in magnitude but are durable and correlate well with RBD Ig
59 binding antibody levels compared to other SARS-CoV-2 antigen responses. In our cohort,
60 higher neutralizing antibody titers are independently and significantly associated with male sex
61 compared to female sex. We also show for the first time, that higher convalescent antibody titers
62 in male donors are associated with increased age and symptom grade. Furthermore, cardio-
63 metabolic co-morbidities are associated with higher antibody titers independently of sex. Here,
64 we present an in-depth evaluation of serologic, demographic, and clinical correlates of
65 functional antibody responses and durability to SARS-CoV-2.

66
67
68
69
70
71
72
73
74
75
76

77 Introduction

78 Over twelve months have passed since the emergence and eventual global spread of the novel
79 coronavirus, SARS-CoV-2, the agent of the COVID-19 pandemic. As SARS-CoV-2 continues to
80 spread and mutate across naïve and previously exposed populations, increased understanding
81 of the breadth and durability of individual humoral responses to natural infection is needed to
82 assess the re-infection risk of individuals and also to guide the deployment and to inform
83 recently authorized vaccines and antibody-based therapies. Recent work has shown that SARS-
84 CoV-2 can stimulate the production of highly neutralizing antibodies directed against the spike
85 protein (S) which is necessary for viral attachment, fusion and entry into host cells(1, 2). We and
86 others have shown that antibodies directed against the ACE2 receptor binding domain (RBD) of
87 the S protein consistently demonstrate a strong correlation with functional neutralization (3-5),
88 and are protective in non-human primate and rodent models (6-9). Furthermore, low
89 conservation between the RBD of SARS-CoV-2 and other non-SARS human
90 betacoronaviruses, makes RBD an appealing target for highly specific COVID-19 responses.

91 Serum antibody responses to endemic betacoronaviruses initially wane weeks to months after
92 infection, but remain detectable up to at least 1 year (10, 11). After SARS-CoV-1 and MERS
93 infections, IgG levels peak at four months, then slowly wane but remain detectable for at least
94 two years and up to 17 years (11, 12). Although antibody seroconversion to primary SARS-CoV-
95 2 infection is nearly universal within the first two weeks after symptom onset (4, 13-15), the
96 magnitude of this response varies with symptom severity (4, 16, 17). Longevity of serum
97 antibodies to SARS-CoV-2 S protein after vaccination as well as natural infection has been
98 studied out to three months, during which time IgG, IgM and IgA levels to most SARS-CoV-2
99 antigens peak and begin to decline (16, 18-20), as plasmablast and short-lived plasma cell
100 responses wane. More recent data suggests that S protein IgG levels begin to reach a steady
101 level with much slower rates of decline after 90 days post infection (5, 21, 22). Few studies have
102 described long-term durability of SARS-CoV-2 wild-type (WT) virus neutralizing antibodies in
103 recovered individuals, and the protective titer of these antibodies is unknown.

104 The clinical and demographic determinants of the breadth and durability of functionally
105 neutralizing antibodies, have not been studied in-depth after SARS-CoV-2 infection. A recent
106 study found higher ratios of RBD antibodies to nucleocapsid (N) antibodies in outpatient
107 compared to inpatient populations (4). Another study found positive correlations with RBD and
108 neutralizing antibody levels with male sex, age and symptom severity in a mild disease cohort
109 60 days post symptom onset (23). Finally, studies have suggested that there is a faster decline
110 in S antibody levels acutely after infection in asymptomatic individuals, compared to
111 symptomatic individuals (4, 17). These early findings in binding and neutralizing antibody levels
112 within the first 30-60 days post infection, indicate that there are significant demographic and
113 clinical differences in humoral immune responses to COVID-19 infection. Identifying these
114 differences is critical to understanding long term protection from natural infection as well as
115 vaccine-induced immunity. In this study, we use both novel and established assays to
116 characterize the binding and longevity of serum antibodies to SARS-CoV-2 RBD, spike protein
117 N-terminal domain (NTD) and N antigens, and to measure the level and durability of SARS-
118 CoV-2 neutralizing antibodies. We further define demographic and clinical correlates of the
119 magnitude and durability of both binding and functional antibody responses to SARS-CoV-2.

120

121

122 **Results**

123 *Donor characteristics*

124 Between April 11th and July 22nd 2020, a total of 101 eligible COVID-19 convalescent plasma
125 (CP) donors were enrolled in this study. The majority of donors donated once, however 31
126 donors provided sequential donations amounting in an additional 48 serum samples. Donors
127 were over 18 years of age, 51% male and 49% female (based on sex assigned at birth). The
128 median age was 43 years (Interquartile Range 29, full range 18-79), which is similar to other CP
129 donor cohorts (22, 23) and the majority identified as non-Hispanic, white/Caucasian. Donors
130 were diagnosed with COVID-19 by either SARS-CoV-2 reverse-transcriptase polymerase chain
131 reaction (RT-PCR) ($n = 79$) or blood antibody testing by EUA approved commercial assays ($n =$
132 22) (Table 1 & Supplementary Table 1). Donors diagnosed by antibody test had either RT-PCR-
133 confirmed household contacts, COVID-19 symptoms without RT-PCR testing, or unable to
134 provide a copy of their RT-PCR result. The median time from symptom onset or RT-PCR
135 diagnosis to first donation was 57 days (full range 21-121). Thirty-four donors reported comorbid
136 conditions, the most common being hay fever and high blood pressure (Supplementary Table
137 2). Eight donors were asymptomatic and 93 reported symptoms. The median time of symptom
138 duration for symptomatic donors without ongoing symptoms (72/90) was 16 days (full range 2-
139 107). Fifty-seven donors had mild-to-moderate disease (Grade 1-2; outpatient), 14 donors had
140 severe disease (Grade 3-4; hospitalized), and 22 donors had unknown disease severity (Table
141 1). The most common symptoms reported were fatigue (89%), headache (77%), fever (74%)
142 and muscle aches (73%) (Supplementary Table 3). The majority of donors resided in central
143 North Carolina, with the highest proportion from Orange and Wake counties (Supplementary
144 Fig. 1).

145

146 *Neutralization and binding antibody assays*

147 To investigate in-depth functional antibody responses to SARS-CoV-2 infection at
148 convalescence, we employed two virus neutralization assays, one using an authentic WT
149 SARS-CoV-2 with a luciferase reporter(24), and another using a PSV assay (see Methods). We
150 also measured total Ig binding to the spike protein RBD and NTD, as well as IgG binding to N
151 protein antigen. We found that 98% (99/101) of donors generated antibodies to at least one
152 SARS-CoV-2 antigen or virus (Fig. 1a,b), 92% (93/101) had at least two positive antibody
153 assays, and 65% (65/101) had functional and binding antibodies to all viruses and antigens.
154 Only two donors had negative results in every assay, both were asymptomatic and both
155 diagnosed by an antibody test. We found that the most sensitive assays to detect antibodies in
156 recovered donors were the RBD total Ig assay (96% of donors positive), followed by PSV
157 neutralization and N IgG assays (both 93% of donors positive).

158 All donors with undetectable RBD antibody titers also had undetectable neutralizing antibody
159 assays, and the RBD binding assay showed the strongest correlation with the two neutralization
160 assays (Fig. 1c-f, Supplementary Fig. 2). Among the other binding assays, the N assay had the
161 weakest correlations with both neutralization assays compared to the spike antigen based NTD
162 assay. We then looked at quantitative measures of functionally neutralizing as well as RBD-
163 binding antibody levels by end-point titer. The majority of donors (80%) had detectable WT
164 neutralizing antibody titers, and > 50% of these exceeded 1:160 (the FDA-recommended
165 threshold for therapeutic applications of convalescent plasma) (Supplementary Fig. 3). The
166 majority of RBD total Ig end-point titers were found to be within the range of 1:160-1:640. Since

167 isotype specific IgA and to a lesser extent, IgM antibodies may influence the early neutralizing
168 antibody response (25), we also measured RBD IgA and IgM binding titers. Approximately 60%
169 of donors demonstrated detectable IgA or IgM antibodies to RBD, with most in the lower titer
170 range (1:20-1:159) (Supplementary Fig. 3).

171

172 *Functional and binding antibody level durability*

173 Overall donor antibody levels, including additional donations from 31/101 donors who donated
174 more than once (total samples donated n=149), revealed stable neutralizing, RBD, and NTD-
175 binding antibodies over six months (Fig. 2). Among the specific assays, neutralizing antibodies
176 to WT virus and binding antibodies to NTD were the most stable out to 180 days (Fig. 2a,b).
177 Through 120 days and beyond, there was a slight decrease in PSV neutralizing antibodies and
178 total Ig binding antibodies to RBD (Fig. 2c,d). RBD total Ig decreases over time were likely due
179 in part to the decline of IgA and IgM titers that we observed after day 90 (Fig. 2e,f). Notably,
180 compared with antibodies directed against spike protein antigens, there was a stronger
181 decrease in N binding IgG levels over this time period (Fig. 2g). When comparing the correlation
182 coefficients of the trendlines in Fig. 2a-d,g with a Fisher r-to-z transformation, we found
183 significant ($p < 0.05$) differences only between NTD antibody levels compared to all of the other
184 assays which either stay constant or decrease.

185 We then studied in detail the donors who provided sequential donations to examine temporal
186 kinetics of antibody levels at an individual level. Overall functional neutralizing antibody levels to
187 WT virus and RBD-binding Ig levels showed no significant changes between donation times
188 (Fig. 3a,b and Supplementary Fig. 4). To ascertain if initial antibody titer plays a role in antibody
189 changes over time, we separated sequential donors into three groups by initial titer: $> 1:640$,
190 $1:160-1:640$, and $1:20-1:159$. Median WT viral neutralization antibody titers (Fig. 3c-e) and RBD
191 Ig antibody titers (Fig. 3f-h) between the first two donations showed a modest decrease in the
192 highest initial titer group ($>1:640$), but not in the lower titer groups. However, earlier time points
193 are needed in the lower titer groups to better compare these levels to the high titer group, as we
194 may not see changes in the lower titer groups due to longer time to first donation in these
195 groups. This decrease in the RBD total Ig group with initial titer $> 1:640$ was likely due to RBD
196 IgA and IgM levels in these donors, which showed a significant decline between the first two
197 donations ($p < 0.05$) (data not shown).

198

199 *Demographic and clinical correlates of functional antibody titers*

200 SARS-CoV-2 binding and functionally neutralizing antibody levels were higher in males
201 compared to females (Fig. 4a,b, Supplementary Fig. 5), and increased with increasing age and
202 correlate positively with male age and symptom grade (Fig. 4c,d). This difference between
203 males and females (Fig. 4a,b) remained after negative data points were removed from each
204 analysis. Surprisingly, positive correlations with antibody levels and age and symptom grade
205 (Fig. 4c,d, Extended Data Fig. 4) were restricted to the male population (Fig. 4e,f). Sex
206 stratification revealed that in males, age and symptom grade were significantly positively
207 correlated, as were age and RBD Ig and functionally neutralizing antibody levels (Fig. 4e,g-k).
208 On the other hand, in females, only RBD IgA levels were associated with symptom grade (Fig.
209 4f). Males and females were equally likely to be hospitalized ($p = 0.95$).

210 We then examined the possibility that antibody stability over time was influenced by sex or age.
211 No significant differences were observed in WT neutralizing antibody levels or RBD Ig levels
212 over time (first 90 days) between males and females (Fig. 5a,b). In contrast, there were rapid
213 declines in both types of antibodies in the youngest age group (18-43yo) over the first 90-day
214 period (Fig. 5c,d) that may have been related to decreases in serum RBD IgA, but not IgM,
215 which showed a significant decline in this age group over this time period (Fig. 5e). We then
216 calculated an estimate of the effect of age, adjusted for time from symptom onset to donation,
217 stratified by sex on the various functional and binding antibody levels. Among males we
218 observed that for each one year increase in age there was a significant increase in antibody
219 levels in all assays tested except N IgG and RBD IgM, but among females age did not seem to
220 affect antibody levels after accounting for time from symptom onset (Fig. 5f).

221 Since we identified that in male donors, increased symptom grade, or disease severity
222 correlated with higher antibody levels, we looked more closely at individual symptoms to
223 ascertain if any in particular were associated with each other, or with donor serum antibody
224 levels. We found that of the most common symptoms, only loss of sense of taste and smell
225 were associated, though more strongly in female than male donors (Supplementary Fig. 7a, b).
226 Surprisingly, we found a negative effect of reporting tiredness or fatigue in male donors on the
227 level of RBD Ig binding antibodies (Supplementary Fig. 7b). We also evaluated the association
228 between antibody levels and the presence of comorbid conditions and found that donors with
229 cardio-metabolic diseases had higher levels of neutralizing, RBD Ig, N IgG and NTD Ig
230 antibodies. This observation was independent of sex. Symptom duration (Supplementary Fig.
231 5k-q,4), nulliparity and ABO blood group were not significantly associated with functional or
232 binding antibody levels.

233

234 Discussion

235 In-depth serological, clinical and demographic correlates of durable and protective functional
236 antibodies in individuals who have recovered from COVID-19 have not been well described.
237 Understanding serological responses to COVID-19 disease and vaccination, will allow us to
238 define which antibody populations may be protective against reinfection and thus act as
239 immunological correlates of protection. Of 101 convalescent plasma donors who experienced a
240 range of COVID-19 disease, the vast majority have detectable levels of functionally neutralizing
241 as well as binding antibodies to SARS-CoV-2 RBD, NTD and N antigens. Furthermore, though
242 their titers are heterogeneous, most donors have neutralizing and RBD-targeting antibody titers
243 of >1:160. Even low levels of functionally neutralizing antibodies to SARS-CoV-2, as seen here
244 in about a quarter of donors, are protective in non-human primate vaccine models (26, 27). This
245 suggests that low serum levels of a few highly potent antibodies may be enough to confer
246 protection, and we find that such antibodies are nearly universally produced upon exposure to
247 the virus in this donor cohort of mostly symptomatic cases.

248 Of three SARS-CoV-2 antigens used for antibody detection in this study, the RBD was the most
249 sensitive in detecting prior SARS-CoV-2 infection. Furthermore, RBD total Ig levels showed the
250 strongest correlation with functionally neutralizing antibodies, suggesting its role as the
251 immunodominant antigenic target of antibodies that neutralize SARS-CoV-2 infection. We found
252 that 95% of sera with an RBD total Ig titer of $\geq 1:160$ had positive WT virus neutralizing antibody
253 titers, suggesting that this may be a cutoff used as a surrogate for functional antibody assays.
254 Furthermore, the majority of donors with undetectable WT virus neutralizing antibody levels, had

255 detectable RBD-binding antibodies, suggesting they may have RBD-targeting neutralizing
256 antibodies that are below the assay detection limit. This hypothesis can be tested in future
257 studies using passive transfer mouse protection models. This highlights the potential role for
258 RBD-based antibody assay development and testing as a surrogate for functional antibody
259 assays that could be deployed in the clinical and vaccination setting in a scalable, high-
260 throughput fashion.

261 The strongest demographic correlate of neutralizing antibody levels we found was male sex.
262 Studies have shown that COVID-19 disease is associated with higher morbidity and mortality
263 rates in men compared with women (28). The reason for this finding is unknown, and seems
264 unrelated to CD8+ and CD4+ T cell frequency (22). Sex differences in other respiratory viral
265 disease outbreaks have been seen, for example during the 2009 influenza pandemic where
266 female sex correlated with severe disease in a young cohort in Canada(29). Some viral
267 infections as well as vaccinations such as the influenza vaccination have been seen to elicit
268 stronger serum antibody and cellular immune responses in females(30), while others elicit
269 stronger serologic antibody responses in males(31). Differences in disease severity and
270 humoral responses to vaccines have been hypothesized to be influenced by a combination of
271 sex hormone effects on immune cell signaling, X chromosome immune-related gene expression
272 and miRNA levels, and genetic polymorphisms (30) in genes encoding important immunologic
273 proteins such as IL-6 (32) and CTLA-4 (33).

274 Robbiani *et al.* reported significantly higher SARS-CoV-2 RBD antibodies and functionally
275 neutralizing antibodies in male compared to female COVID-19 CP donors with mild-moderate
276 disease in the first 60 days post symptom onset (23). Similarly, we find significant correlations of
277 higher functional and binding antibody levels with male sex, continued out to 180 days. We
278 further add that these sex differences in antibody levels are also seen with SARS-CoV-2 N
279 protein and NTD antigens, and that age and symptom grade also influenced the sex disparity in
280 RBD binding and functionally neutralizing antibody responses. These findings suggest that male
281 sex, especially males with increased age and worse COVID-19 symptom severity may be a
282 demographic and clinical correlate of functional antibodies. Studies have shown that early
283 convalescent functional antibody levels are higher in individuals with more severe COVID-
284 19(16, 19), which may be a product of prolonged viral replication and immune antigenic
285 exposure. Our findings recognize that there are currently unknown underlying factors which
286 predispose older males to either prolonged viral replication and immune exposure to SARS-
287 CoV-2, or differential immune activation.

288 We do not yet know what level of functional antibodies is required for protection from SARS-
289 CoV-2. Although female donors in this cohort have lower antibody levels than males, this may
290 be enough to confer long-term protection. This observation warrants further investigation,
291 including consideration of a similar sex-bias in vaccine-induced immunity. Furthermore, we
292 found significant differences in sex and functional antibody production despite reported disease
293 severity, suggesting that pro-longed viremia and/or abnormal cytokine activation may not be the
294 only things responsible for this finding. Other hypotheses that have been made to explain
295 COVID-19 disease sex differences include poorer T cell responses in males (28), and the
296 presence of previously undetected auto-antibodies against Type I interferons (34) in males with
297 severe disease. On the other hand, the hypothesis that expression of ACE2 and TMPRSS,
298 important SARS-CoV-2 cellular entry receptors in human lung and other tissues, play a role in
299 the sex disparity is thought to be an unlikely explanation (35).

300 In the face of COVID-19 vaccinations and new viral mutations, it is critical to define functional
301 antibody durability after natural infection and vaccination. Here we show for the first time, that
302 functionally neutralizing antibodies to WT SARS-CoV-2 virus remain stable months post
303 symptom onset, and that this is likely maintained to 180 days. Not surprisingly, levels of RBD-
304 binding IgA and IgM antibodies declined rapidly within the first three months after symptom
305 onset. However, NTD-binding Ig antibodies remain stable, and RBD-binding Ig antibodies
306 declined modestly. Levels of WT neutralizing and RBD Ig antibodies on an individual level were
307 also maintained, with only a modest decrease within the first 90 days after symptom onset in
308 donors with initial titers > 1:640. When broken down by age group, 18-34 year old donors
309 demonstrated a significant decrease in functional antibody and RBD Ig responses over the first
310 90 days post symptom onset that was likely driven by rapidly declining RBD IgA levels.

311 We also find that N IgG antibodies correlate least with neutralizing antibodies and continue to
312 decline 120-180 days post symptom onset, a trend which was noted 90 days post symptom-
313 onset in a mild-disease community cohort (18). This suggests that though SARS-CoV-2 N
314 antibodies may be generated at high levels early after symptomatic infection, N may not be an
315 immunodominant target of the adaptive immune response, and thus is a less sensitive measure
316 of remote infection. This further suggests that the use of N protein in seroprevalence studies
317 may bias results towards more recent infections and warrants further investigation in cohorts of
318 mild and asymptomatic COVID-19 disease.

319 One major limitation of this study is the demographic uniformity of our study population, which
320 limits the generalizability of our findings and highlights the need to do these studies with a more
321 diverse and representative population. Another bias in our donor population is our focus on re-
322 calling donors with higher neutralizing antibody titers to repeat donations. Thus, our “sequential
323 donation” population is biased towards higher titer donors.

324 Understanding human antibody responses and correlates of neutralizing antibodies to SARS-
325 CoV-2 is critical in the next coming phase of understanding SARS-CoV-2 vaccine efficacy and
326 protection against reinfection. We find that WT SARS-CoV-2 functionally neutralizing antibodies
327 are maintained for months after infection. Our findings further support the role of RBD binding
328 antibodies as correlates of functionally neutralizing antibodies, suggesting that vaccines that
329 induce potent RBD responses may be particularly efficacious. Furthermore, we identify for the
330 first time, a role for sex differences as sustained correlates of WT SARS-CoV-2 functional
331 neutralization. The association of male sex in this cohort with higher neutralizing antibody levels
332 reveals a sexual dimorphism in humoral immune responses to SARS-CoV-2. We hypothesize
333 that this is likely due to a combination of factors such as differences in duration of mucosal
334 replication, T cell responses, sex hormone roles in immune activation, and genetic differences in
335 immune responses. This finding may have clinical as well as vaccine outcome implications, and
336 warrants further investigation.

337

338

339

340

341

342

343
344
345
346
347
348

Methods

349 *Donors and Plasma Collection*

350 Convalescent plasma was obtained from volunteer donors who met FDA criteria for plasma
351 collections in the UNC Blood Donor Center. Donors were recruited via IRB-approved direct
352 contact of SARS-CoV-2 positive persons diagnosed through the hospital laboratory system, and
353 public solicitation through multi-media outlets. Fresh sera and plasma collected in the diversion
354 pouch as part of the standard plasmapheresis procedure was saved for research from donors
355 consented to study participation. All donors had confirmed COVID-19 infection by blood
356 antibody testing or nasopharyngeal swab indicating the presence of SARS-CoV-2 RNA as
357 performed by RT-PCR in a US laboratory with a Clinical Laboratory Improvement Amendments
358 certification. All donors were recovered from their COVID-19 illness and qualified for collection
359 in adherence with FDA-regulatory guidance. As required at the time, some donors had a
360 negative repeat SARS-CoV-2 RT-PCR test done within 72 hours prior to donation. At the time of
361 plasma collection, donors were offered participation in the study. All donors who participated
362 provided written informed consent. The research was approved by the UNC Institutional Review
363 Board, and conducted under good clinical research practices. Participating donor characteristics
364 and information regarding COVID-19 symptoms and history were obtained through in-person
365 and telephone interviews using a standardized questionnaire as part of UNC IRB #20-1141. We
366 generated a 4-point symptom severity scale for this study based on the DAIDS grading
367 system(36). For this study time period we did not pre-screen donors to determine presence of
368 SARS-CoV-2 antibodies, donor qualifications were based strictly on their positive COVID-19
369 diagnostic test and eligibility for plasma donation.

370

371 *Recombinant SARS-CoV-2 spike protein antigens*

372 The production of RBD antigen from SARS-CoV-2 was previously described (3). The NTD
373 antigen (16–305 amino acids, Accession: P0DTC2.1) was cloned into the pαH mammalian
374 expression vector and purified using nickel-nitrilotriacetic acid agarose in the same manner.

375

376 *Enzyme-linked Immunosorbent Assays*

377 The RBD ELISA assay used in this study was initially described here (3), and the NTD ELISA
378 was performed in the same manner. Briefly ELISAs were done either as a single-point dilution at
379 1:40 or as serial titrations starting at a dilution of 1:20 or 1:40. ELISA plates were coated with
380 200ng/well of antigen and blocked, a 2-fold serum dilution series was done and diluted sera was
381 incubated for 1hr at 37°C. Alkaline-phosphatase linked secondary antibodies were used at
382 1:2500 dilution (IgM and IgG, Sigma; IgA, Abcam). PNPP substrate (Sigma) was added to
383 develop the plate and absorbance was measured at 10 minutes for total Ig, IgG or 25 minutes
384 for IgA or IgM at 405nm using a plate reader (BioTek). Each sample was performed in duplicate.

385 Antibody titration measurements were recorded as end-point titers. Ten plasma samples were
386 tested in the RBD total Ig format and compared to serum, all titer results were within a 2-fold
387 dilution (data not shown). ROC analyses were done to obtain cutoff values and sensitivity and
388 specificity estimates on the SARS-CoV-2 assays using pre-2019 negative control sera and RT-
389 PCR confirmed COVID-19 cases that were at least nine days post-symptom onset
390 (Supplementary Table 4). Positive and negative controls were used to standardize each ELISA
391 assay and normalize across experiments.

392

393 *Nucleocapsid protein ELISA*

394 Detection of IgG antibody to SARS-CoV-2 N antigen was performed with a microparticle
395 chemiluminescence assay (Abbott Laboratories) on the Abbott Architect i2000SR immunoassay
396 analyzer. The EUA approved Abbott SARS-CoV-2 IgG assay utilizes microparticles coated with
397 SARS-CoV-2 N protein to capture N specific IgG. Bound IgG was detected via addition of anti-
398 human acridinium-labeled second-step antibody. Following a second wash step, pre-trigger and
399 trigger solutions were added and a chemiluminescent reaction was detected and reported in
400 relative light units (RLU). The RLU generated is reflective of the amount of antibody bound to
401 the microparticles. The sample RLU was compared to the assay-specific calibrator RLU to
402 generate an index value (S/C). Index values ≥ 1.4 were considered positive. Sensitivity and
403 specificity has been previously obtained for this assay (Supplementary Table 4) (37, 38).

404

405 *SARS-CoV-2-WA1 neutralization assay*

406 Full-length SARS-CoV-2 viruses expressing a nano-luciferase gene were designed and
407 recovered via reverse genetics as previously described (3, 24) in a 96-well micro neutralization
408 format. Briefly, Vero E6 cells were infected with SARS-2-pLuc viruses and titered to generate an
409 8-point curve. Initial serum dilutions to detect the presence of neutralizing antibody were 1:20 or
410 1:50, and all serum samples were tested in duplicate. Internal serum controls, cell-only controls,
411 and virus-only controls were included in each neutralization assay plate. Plates were incubated
412 for 48 hours, at which point cells were lysed and luciferase activity was measured on a Nano-
413 Glo Luciferase Assay System (Promega). Antibody neutralization titers to SARS-CoV-2 were
414 reported as serum dilutions at which a 50% reduction in relative light units (NT50) to virus-only
415 controls were observed. LOD was set to 1:10, or $\frac{1}{2}$ the starting dilution of 1:20, since all NT50
416 values above a titer of 1:10 that were run with a 1:50 starting dilution were $> 1:25$. Thirteen
417 plasma samples were tested and compared to serum, all NT50 results were within a 3-fold
418 dilution (data not shown). Pre-COVID-19 serum samples were also tested, and 13/13 had NT50
419 $< 1:20$ in this assay.

420

421 *SARS-CoV-2 Pseudovirus neutralization assay*

422 The “PhenoSense SARS CoV-2 nAb Assay” has been developed by leveraging the proprietary
423 PhenoSense Assay platform that was developed to evaluate antiretroviral drug susceptibility(39)
424 and later adapted to evaluate entry inhibitors and neutralizing antibody(40) as well as co-
425 receptor tropism(41). The production of luciferase is dependent on virus entry and the
426 completion of a single round of virus replication. Agents that inhibit pseudovirus entry or

427 replication reduce luciferase activity in a dose-dependent manner, providing a quantitative
428 measure of drug and antibody susceptibility.

429 The measurement of neutralizing antibody activity using the PhenoSense SARS CoV-2 nAb
430 Assay is performed by generating HIV-1 pseudovirions that contain and express the complete
431 SARS CoV-2 spike protein open reading frame. The pseudovirus is prepared by co-transfecting
432 HEK293 producer cells with an HIV-1 genomic vector and a SARS CoV-2 envelope expression
433 vector. Neutralizing antibody activity is measured by assessing the inhibition of luciferase
434 activity in HEK293 target cells expressing the ACE2 receptor following pre-incubation of the
435 pseudovirions with serial dilutions of the serum specimen. The expression of luciferase activity
436 in target cells is inhibited in the presence of anti-SARS CoV-2 neutralizing antibody. Data are
437 displayed by plotting the percent inhibition of luciferase activity against \log_{10} reciprocal of the
438 serum/plasma dilution. Neutralizing antibody titers are reported as the reciprocal of the serum
439 dilution conferring 50% inhibition (NT50) of pseudovirus infection.

440

$$\%Inhibition = 100\% - \left(\left(\frac{RLU(Vector + Sample + Diluent) - RLU(Background)}{RLU(Vector + Diluent) - RLU(Background)} \right) \times 100\% \right)$$

441

442 The results of the PhenoSense SARS CoV-2 nAb Assay can be reported as an NT50 titer
443 (1/Dilution) or qualitatively (positive, negative) based on a pre-defined dilution cutoff (e.g. >50%
444 inhibition at 1:40 dilution). To insure that the measured neutralizing antibody activity is SARS
445 CoV-2 specific, each test specimen is also assessed using a non-specific pseudovirus
446 (specificity control) that expresses a non-reactive envelope protein of one or more unrelated
447 viruses (e.g. avian influenza virus).

448

449 *Statistical analyses*

450 We used the Wilcoxon rank-sum test to test for differences between two groups and the
451 Kruskal-Wallis test followed by Benjamini-Yekutieli correction to test for differences between
452 three or more groups. We calculated the phi coefficient as a measure of association between
453 two binary factors and relied on the Chi-square test to test for differences. We also calculated
454 the Spearman's rank correlation coefficient, and used locally estimated scatterplot smoothing
455 (LOESS) to visualize antibody trends over time. Linear regression models were used to further
456 assess relationships with antibody levels, after first transforming antibody levels to the base-2
457 logarithm scale. Venn diagram and correlation heat maps were created to visualize
458 associations. All statistical analyses were performed using R 4.0.2 (Vienna, Austria), all tests
459 were two-sided and a P-value <0.05 was considered statistically significant.

460

461

462

463

464

465

466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505

Acknowledgements

We would like to thank all of our UNC CP donors, the staff at the UNC Blood Donation Center including Hannah Thaxton and Taylor A. Whitaker, and the many volunteers who contributed to this work. This project was supported by the UNC Health Foundation and the North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly. The NIH SeroNet SeroCenter of Excellence Award, U54 CA260543, supported generation of laboratory data and the following investigators: AJM, LP, SN, SW, DMM, ADS, RB, and LAB. AJM was previously funded by an NIH NIAID T32 AI007151. SN is also funded by the following NIH grants: UNC Center for AIDS Research (P30 AI50410), NA-ACCORD COVID-19 Supplement (U01 AI069918). DRM is funded by an NIH F32 AI152296, a Burroughs Wellcome Fund Postdoctoral Enrichment Program Award, and was previously funded by an NIH NIAID T32 AI007151.

Author Contributions

AJM performed experiments, data analysis and interpretation, and contributed to writing the manuscript. NG performed data and statistical analyses and contributed to writing the manuscript. DRM and XJH performed neutralization experiments and analysis. RR, PL, DRB, SDG and QG performed experiments. AL contributed to writing the manuscript. HR performed data analysis. CC and JS performed the N IgG Abbott assays. DMM and LB executed the clinical protocols, contributed to data analysis and interpretation, and contributed to the manuscript. JK, SW and YP executed the clinical protocols and coordinated donations and collection. SN contributed to statistical analyses and editing the manuscript. DVD edited the manuscript. CJP and TW generated, executed and completed data analysis of the PSV neutralization assay. Funding for the project was obtained by RB, ADS, DMM, and LAB.

Competing Interests statement

CJP and TW are employees of Laboratory Corporation of America/Monogram Biosciences.

506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548

References

1. Brouwer PJM, *et al.* (2020) Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science*.
2. Suthar MS, *et al.* (2020) Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. *Cell Rep Med* 1(3):100040.
3. Premkumar L, *et al.* (2020) The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol* 5(48).
4. Roltgen K, *et al.* (2020) Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. *Sci Immunol* 5(54).
5. Wajnberg A, *et al.* (2020) Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 370(6521):1227-1230.
6. Rogers TF, *et al.* (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* 369(6506):956-963.
7. Yu F, *et al.* (2020) Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. *Signal Transduct Target Ther* 5(1):212.
8. Zost SJ, *et al.* (2020) Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* 584(7821):443-449.
9. Baum A, *et al.* (2020) REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. *Science*.
10. Callow KA, Parry HF, Sergeant M, & Tyrrell DA (1990) The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect* 105(2):435-446.
11. Huang AT, *et al.* (2020) A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun* 11(1):4704.
12. Lin Q, Zhu L, Ni Z, Meng H, & You L (2020) Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection. *J Microbiol Immunol Infect*.
13. Lou B, *et al.* (2020) Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. *Eur Respir J*.
14. To KK, *et al.* (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 20(5):565-574.
15. Zhao J, *et al.* (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis*.
16. Crawford KHD, *et al.* (2020) Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *J Infect Dis*.

- 549 17. Long QX, *et al.* (2020) Clinical and immunological assessment of asymptomatic SARS-CoV-2
550 infections. *Nat Med* 26(8):1200-1204.
- 551 18. Ripperger TJ, *et al.* (2020) Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-
552 Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity* 53(5):925-933 e924.
- 553 19. Seow J, *et al.* (2020) Longitudinal observation and decline of neutralizing antibody responses in
554 the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* 5(12):1598-1607.
- 555 20. Widge AT, *et al.* (2020) Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N*
556 *Engl J Med*.
- 557 21. Gudbjartsson DF, *et al.* (2020) Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J*
558 *Med* 383(18):1724-1734.
- 559 22. Dan JM, *et al.* (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after
560 infection. *Science*.
- 561 23. Robbiani DF, *et al.* (2020) Convergent antibody responses to SARS-CoV-2 in convalescent
562 individuals. *Nature* 584(7821):437-442.
- 563 24. Hou YJ, *et al.* (2020) SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the
564 Respiratory Tract. *Cell*.
- 565 25. Sterlin D, *et al.* (2020) IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci*
566 *Transl Med*.
- 567 26. Gao Q, *et al.* (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. *Science*
568 369(6499):77-81.
- 569 27. Yu J, *et al.* (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*
570 369(6505):806-811.
- 571 28. Takahashi T, *et al.* (2020) Sex differences in immune responses that underlie COVID-19 disease
572 outcomes. *Nature*.
- 573 29. Zarychanski R, *et al.* (2010) Correlates of severe disease in patients with 2009 pandemic
574 influenza (H1N1) virus infection. *CMAJ* 182(3):257-264.
- 575 30. Klein SL (2012) Sex influences immune responses to viruses, and efficacy of prophylaxis and
576 treatments for viral diseases. *Bioessays* 34(12):1050-1059.
- 577 31. Cook IF (2008) Sexual dimorphism of humoral immunity with human vaccines. *Vaccine* 26(29-
578 30):3551-3555.
- 579 32. Cussigh A, *et al.* (2011) Interleukin 6 promoter polymorphisms influence the outcome of chronic
580 hepatitis C. *Immunogenetics* 63(1):33-41.
- 581 33. Schott E, *et al.* (2007) Gender-dependent association of CTLA4 polymorphisms with resolution of
582 hepatitis C virus infection. *J Hepatol* 46(3):372-380.
- 583 34. Bastard P, *et al.* (2020) Autoantibodies against type I IFNs in patients with life-threatening
584 COVID-19. *Science* 370(6515).
- 585 35. Baughn LB, *et al.* (2020) Targeting TMPRSS2 in SARS-CoV-2 Infection. *Mayo Clin Proc* 95(9):1989-
586 1999.
- 587 36. DAIDS (2017) Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric
588 Adverse Events. ed Events DoADTfGtSoAaPA (NIAID, NIH, Bethesda, MD).
- 589 37. Nicol T, *et al.* (2020) Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19
590 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and
591 Abbott) and one rapid lateral flow immunoassay (NG Biotech). *J Clin Virol* 129:104511.
- 592 38. FDA (2020) EUA Authorized Serology Test Performance.
- 593 39. Petropoulos CJ, *et al.* (2000) A novel phenotypic drug susceptibility assay for human
594 immunodeficiency virus type 1. *Antimicrob Agents Ch* 44(4):920-928.
- 595 40. Richman DD, Wrin T, Little SJ, & Petropoulos CJ (2003) Rapid evolution of the neutralizing
596 antibody response to HIV type 1 infection. *P Natl Acad Sci USA* 100(7):4144-4149.

597 41. Whitcomb JM, *et al.* (2007) Development and characterization of a novel single-cycle
598 recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor
599 tropism. *Antimicrob Agents Ch* 51(2):566-575.

600

601 **Figure legends:**

602 **Fig. 1 Neutralizing and binding antibody results.** **a**, Pie chart with overall assay results for all
603 101 donors, four assays shown (wild-type neutralization assay, RBD and NTD total Ig assays,
604 Nucleocapsid IgG assay), **b**, Venn diagram showing overlap among five assays (wild-type
605 neutralization assay, pseudovirus neutralization assay, RBD and NTD total Ig assays,
606 Nucleocapsid IgG assay), **c**, Heat map of Spearman's correlation coefficients examining the
607 association between all assays performed. Red colour represents positive association between
608 assays and black represents negative associations. Not significant correlations coefficients
609 ($p>0.05$) are left blank, **d**, Wild-type virus NT50 dilution plotted against pseudovirus NT50
610 dilution, $p<0.0001$, **e**, Wild-type virus NT50 dilution plotted against RBD total Ig antibody level
611 (end-point titer), $p<0.0001$. **f**, Pseudovirus NT50 dilution plotted against RBD total Ig antibody
612 level (end-point titer), $p<0.0001$. For **d-f**, non-parametric, two-tailed Spearman's rank correlation
613 was used to calculate correlation coefficients (r) and P values (p), titers below LOD set to 5, all
614 double-negative values removed, blue lines represent linear regression fit with 95% confidence
615 interval (gray shading).

616 **Fig. 2 Antibody titers over time.** **a**, Functional antibody (WT NT50 dilution) plotted against
617 days post symptom onset or RT-PCR diagnosis, $r=-0.041$, $p = 0.63$, **b**, Functional antibody
618 (PSV NT50 dilution) plotted against days post symptom onset or RT-PCR diagnosis, $r=-0.21$,
619 $p=0.014$. **c**, Nucleocapsid IgG (index value) plotted against days post symptom onset or RT-
620 PCR diagnosis, $r=0.092$, $p=0.0029$, **d**, NTD total Ig (P/N ratio) plotted against days post
621 symptom onset or RT-PCR diagnosis, $r=0.092$, $p=0.28$, **e**, RBD total Ig (end-point titer) plotted
622 against days post symptom onset or RT-PCR diagnosis, $r=-0.18$, $p=0.033$, **f**, RBD IgM (end-
623 point titer) plotted against days post symptom onset or RT-PCR diagnosis, $r=-0.39$, $p<0.0001$, **g**,
624 RBD IgA (end-point titer) plotted against days post symptom onset or RT-PCR diagnosis, $r=-$
625 0.41 , $p<0.0001$. For **a-g**, $n=138$, non-parametric, two-tailed Spearman's rank correlation was
626 used to calculate correlation coefficients (r) and P values (p), titers below LOD set to 5, all
627 double-negative values removed, blue lines represent loess regression fit with 95% confidence
628 interval (gray shading).


629 **Fig. 3 Antibody titers over time in sequential donors.** **a**, Functional antibody (NT50 dilution)
630 of sequential donors over four donations. **b**, RBD total Ig titers of sequential donors over four
631 donations. **c-e**, Functional antibody (NT50 dilution) stratified by titer levels at first donation. **f-h**,
632 RBD total Ig stratified by titer levels at first donation. Titers are presented as geometric mean
633 with geometric coefficient of variation. Statistical significance was determined using non-
634 parametric Kruskal-Wallis test adjusted for multiple comparisons for **a-b**. For **c-h** statistical
635 significance was determined using Mann-Whitney U-tests comparing donation 1 vs donation 2
636 for which matching donor data was available.

637 **Fig. 4 Clinical correlates of antibody titers.** **a**, Functional antibody (NT50 dilution) in males
638 ($n=49$) and females ($n=46$) at first donation, **b**, RBD total Ig titers in males and females at first
639 donation. Horizontal bars indicate median values. For **a,b** statistical significance was
640 determined using Mann-Whitney U-tests, **c,d**, Spearman's correlation between age correlation
641 between age and NT50 or RBD Ig levels at first donation, **e,f**, non-parametric, two-tailed,
642 Spearman's correlations heat map of clinical correlates and antibody titers stratified by sex, (red
643 = positive association, blue = negative association, blank = not significant association), **g-k**,
644 correlation between age and NT50 or RBD Ig levels at first donation. Spearman's rank
645 correlation was used to calculate correlation coefficients (r) and P values (p)

646 **Fig. 5 Antibody differences between sexes and age groups.** **a**, Differences in functional
647 antibody (NT50 dilution) levels between males (n=49) and females (n=46) at first donation. **b**,
648 Differences in RBD total Ig titers between males and females at first donation. **c**, Differences in
649 functional antibody (NT50 dilution) levels between age groups. **d**, Differences in in RBD total Ig
650 titers between age groups. For **c-d** Donors were divided into tertiles based on their age. For **a-d**,
651 lines represent linear regression fit and shaded areas represent 95% confidence interval. Lines
652 from linear regression were fitted from day 30-90 to avoid overfitting where fewer observations
653 were available. Spearman's rank correlation was used to calculate correlation coefficients (r)
654 and P values (p) **e**, Forest plot of estimated effect (95% CI) of age on antibody titers at first
655 donation, stratified by sex. Linear regression model was adjusted for time from symptom onset
656 or RT-PCR diagnosis.


657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682

683 **Fig. 1 Neutralizing and binding antibody results**



684

685 **Fig. 2 Antibody titers over time**



686

687

688

689

690


691

692

693


694

695 **Fig. 3 Antibody titers over time in sequential donors**




696
697
698
699
700
701
702

703 **Fig. 4 Clinical correlates of antibody titers**



704

705 **Fig. 5 Antibody differences between sexes and age groups**



706

707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732

Table 1. Convalescent plasma donor characteristics at time of donation			
(n=101 unless otherwise specified)			
Age		Race (n=98)	
18-39	39	White/Caucasian	75
40-64	53	Black/African American	7
65-79	9	Asian	5
80+	0	Pacific Islander	1
		Other	10
Sex		Ethnicity (n=98)	
M	52	Hispanic	15
F	49	Non-Hispanic	82
Parity (n=48)		Unknown	1
Parous	26	ABO (n=99)	
Nulliparous	22	A+	36
Comorbid conditions		A-	7
None	64	B+	7
One	18	B-	1
Two or more	16	AB+	6
Unknown	3	AB-	0
		O+	36
		O-	6
COVID-19 disease characteristics			(n)
RT-PCR diagnosed			79
Antibody diagnosed			22
Diagnostic test unknown			1
Symptomatic			93
Asymptomatic			8
Overall symptom grade (n = 71)			
	1 (mild)		24
	2 (moderate)		33
	3 (severe)		11
	4 (potentially life-threatening)		3
Supplemental oxygen required (n = 71)			6
			(days, range)
Median time from symptom onset or RT-PCR diagnosis to donation (n = 95)			57, 21-121
Median time of symptom duration (n=70)			16, 2-107

733 **Table 1. Convalescent plasma donor characteristics at time of donation.** Plasma donor
734 demographic and COVID-19 disease characteristics. RT-PCR; Reverse-transcriptase
735 polymerase chain reaction. Symptom grades: GRADE 1 MILD; Mild symptoms causing no or
736 minimal interference with usual social & functional activities with intervention not indicated.
737 GRADE 2 MODERATE; Moderate symptoms causing greater than minimal interference with
738 usual social & functional activities with intervention indicated. GRADE 3 SEVERE; Severe
739 symptoms causing inability to perform usual social & functional activities with intervention or
740 hospitalization indicated. Oxygen administered via nasal cannula. GRADE 4 POTENTIALLY
741 LIFE-THREATENING; potentially life-threatening symptoms causing inability to perform basic
742 self-care functions with intervention indicated to prevent permanent impairment, persistent
743 disability, or death. Hospitalization requiring intubation or use of supplemental oxygen (CPAP or
744 oxygen administered via mask).